Drugs, Diseases, and the Managed Care Impact

(D6) AMCP Partner Session: Focus on Rare Diseases: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Thursday, March 23, 2023

4:30 PM – 5:45 PM

Location: 302AB

ACPE UAN:N/A | Contact Hours: N/A | Activity Type: N/A

Faculty(s)

Julie B. Bell, M.ED.

CIPD Patient
GBS-CIDP International Foundation
San Antonio, TX
Lisa Butler (she/her/hers)

Executive Director
GBS|CIDP Foundation International
Conshohocken, PA
Stephanie Spence, PharmD, CSP (she/her/hers)

Program Director, Specialty Pharmacy
CareFirst BCBS
Fort Washington, MD

Moderator(s)

Faisal Riaz, MD

Medical Director PDT RAID/Neuroimmunology
Takeda US Medical Affairs
Lexington, Massachusetts

This educational activity is sponsored by Takeda Pharmaceutical Company and is not accredited for continuing pharmacy education credit.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare disorder that impacts the peripheral nerves and is characterized by gradually increasing sensory loss and weakness. It is theorized that CIDP is an autoimmune condition where the body attacks myelin which covers the nerve axon.

At this time, recommended first-line treatments used to manage CIDP include corticosteroids, plasmapheresis, and high doses of immunoglobulins. Without treatment, about 30% of patients will become wheelchair dependent. Early diagnosis and proper treatment can potentially prevent significant disability.

This session is designed to increase awareness of CIDP among the managed care pharmacy audience. In addition, this session will provide a patient perspective on managing CIDP and address access to care and appropriate treatments.

Learning Objectives::

At the completion of this activity, participants should be able to:

Define Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
Based on current treatment guidelines, discuss the treatment options used to manage CIDP.
From a patient perspective, explain the impact of a CIDP diagnosis and the challenges to gaining access to care and treatment.
Describe two strategies managed care professionals can employ to enhance the patient care journey for a person with CIDP.